Ischaemia–reperfusion (I–R) injury, initiated via bursts of reactive oxygen species produced
during the reoxygenation phase following hypoxia, is well known in a variety of acute …

To facitinib and baricitinib are two of the currently available Janus kinase (JAK) inhibitors for
the treatment of patients with RA. Randomized controlled trials have shown that these JAK …

Somatic mutations in UBA1 involving hematopoietic stem and myeloid cells have been
reported in patients with the newly defined VEXAS (vacuoles, E1 enzyme, X-linked …

Objectives To investigate outcomes of Coronavirus Disease-2019 (COVID-19) in patients
with rheumatoid arthritis (RA) as compared to the general population. Additionally, outcomes …

Background Tofacitinib is an oral, small molecule JAK inhibitor for the treatment of ulcerative
colitis (UC). Aim To report incidence of deep vein thrombosis (DVT) and pulmonary …

Objective To assess the incidence of venous thromboembolism (VTE) in rheumatoid arthritis
(RA) relative to individuals without RA, and to investigate the relationship between aspects …

Objective To assess the frequency of cardiovascular and venous thromboembolic events in
clinical studies of baricitinib, an oral, selective JAK1 and JAK2 inhibitor approved in more …

Two different Janus kinase (JAK) inhibitors—baricitinib and tofacitinib—are effective and
licensed in active rheumatoid arthritis (RA). There have been recent concerns about …

Aims To determine the risk of venous thromboembolism (VTE) defined as the combined
endpoint of deep venous thrombosis (DVT) and pulmonary embolism (PE) among patients …

ABSTRACT Introduction To date, four Janus kinase inhibitors (JAKis) are licensed for the
treatment of rheumatoid arthritis (RA) and/or psoriatic arthritis (PsA) in North America and/or …